More US FDA Departures: ODE II Director Rosebraugh, GI Division Director Griebel to Retire

FDA will have three leadership positions vacant in the Office of Drug Evaluation II when Curtis Rosebraugh leaves at the end of the month. 

FDA entrance sign 2016

Office of Drug Evaluation II Director Curtis Rosebraugh will be retiring from the US FDA effective April 28 at a time when two of the three review divisions he oversees are also undergoing leadership changes.

Division of Pulmonary, Allergy, and Rheumatology Products Director Badrul Chowdhury left FDA April 16 for a position at AstraZeneca and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership